May 3, 2022
In 2005, Pfizer launched a Phase 1 trial for the kinase inhibitor crizotinib. Six years later, it was approved, thanks...
Read article
February 9, 2017
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses in...
Read article
August 31, 2016
Traditional rule-based approaches to dose escalation such as 3+3 are widely used in early clinical development. They...
Read article
August 23, 2016
At the recent JSM meeting in Chicago, Cytel's Jim Bolognese presented the results of work he has conducted evaluating...
Read article
July 21, 2016
Did you miss our webinar on Single and Dual Agent Dose escalation designs earlier in the year? In this blog we have...
Read article
November 10, 2015
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods...
Read article
November 18, 2014
Statisticians and scientists at Novartis have been at the forefront of developing a new method in early phase oncology...
Read article
September 4, 2014
Imagine if we were to count the number of possible reasons that investigators might have for monitoring a biomarker...
Read article
August 21, 2014
Use of the continual reassessment method (CRM) is safe, efficient, and flexible, according to a comprehensive review of...
Read article
July 31, 2014
Statisticians at Cytel are staunch advocates of the use of Bayesian methods in clinical trials. This summer's Joint...
Read article
July 15, 2014
Do you design or analyze Phase 1 dose escalation trials? Have you considered methods other than 3+3? This new Cytel...
Read article
May 8, 2014
( Editor's note: This post has been refreshed in December 2016) Model based algorithms for Phase I dose-escalation have...
Read article
